E. Musch

801 total citations
44 papers, 623 citations indexed

About

E. Musch is a scholar working on Oncology, Epidemiology and Genetics. According to data from OpenAlex, E. Musch has authored 44 papers receiving a total of 623 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Epidemiology and 7 papers in Genetics. Recurrent topics in E. Musch's work include Inflammatory Bowel Disease (6 papers), Drug Transport and Resistance Mechanisms (5 papers) and Hepatitis C virus research (5 papers). E. Musch is often cited by papers focused on Inflammatory Bowel Disease (6 papers), Drug Transport and Resistance Mechanisms (5 papers) and Hepatitis C virus research (5 papers). E. Musch collaborates with scholars based in Germany, Sweden and Czechia. E. Musch's co-authors include U. Loos, Michel Eichelbaum, J.Chris Jensen, Gerd Mikus, T. Andus, Arezou Zargari, Robert Löfberg, Filip Závada, Charlotte Admyre and Stefan Schreiber and has published in prestigious journals such as Journal of Hepatology, Pharmacology & Therapeutics and Alimentary Pharmacology & Therapeutics.

In The Last Decade

E. Musch

43 papers receiving 603 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Musch Germany 14 152 130 127 123 113 44 623
Miriam Barbanti Italy 14 77 0.5× 106 0.8× 165 1.3× 80 0.7× 87 0.8× 23 683
Kazuko Nagase Japan 16 145 1.0× 219 1.7× 114 0.9× 294 2.4× 149 1.3× 36 927
Ward Jm United States 16 262 1.7× 86 0.7× 304 2.4× 80 0.7× 58 0.5× 34 950
Tomonori Hada Japan 18 76 0.5× 117 0.9× 384 3.0× 66 0.5× 135 1.2× 55 1.1k
Melinda J. Reese United States 16 128 0.8× 100 0.8× 156 1.2× 46 0.4× 38 0.3× 18 1.1k
Sarah L. Greig New Zealand 16 230 1.5× 81 0.6× 329 2.6× 85 0.7× 71 0.6× 28 932
Huw B. Jones United Kingdom 17 116 0.8× 144 1.1× 229 1.8× 55 0.4× 85 0.8× 38 801
G. L. Floersheim Switzerland 19 111 0.7× 62 0.5× 257 2.0× 85 0.7× 187 1.7× 71 1.0k
Fang Zhao China 16 124 0.8× 118 0.9× 308 2.4× 53 0.4× 140 1.2× 70 916
George Tang United States 14 201 1.3× 140 1.1× 256 2.0× 73 0.6× 115 1.0× 39 837

Countries citing papers authored by E. Musch

Since Specialization
Citations

This map shows the geographic impact of E. Musch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Musch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Musch more than expected).

Fields of papers citing papers by E. Musch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Musch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Musch. The network helps show where E. Musch may publish in the future.

Co-authorship network of co-authors of E. Musch

This figure shows the co-authorship network connecting the top 25 collaborators of E. Musch. A scholar is included among the top collaborators of E. Musch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Musch. E. Musch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zargari, Arezou, et al.. (2014). Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients. BMC Gastroenterology. 14(1). 79–79. 20 indexed citations
2.
3.
Musch, E., et al.. (2009). Periphere Polyneuropathie und beidseitige Optikusneuropathie unter Behandlung einer chronischen Hepatitis C. DMW - Deutsche Medizinische Wochenschrift. 134(18). 927–930. 5 indexed citations
4.
Musch, E., et al.. (2007). Successful Treatment of Steroid Refractory Active Ulcerative Colitis with Natural Interferon-β - an Open Long-Term Trial. Zeitschrift für Gastroenterologie. 45(12). 1235–1240. 24 indexed citations
5.
Malek, Maryam, et al.. (2007). Experimental Study on the Use of Intravenous Immunoglobulin (IVIg) in Patients with Steroid-Resistant Crohn’s Disease. Zeitschrift für Gastroenterologie. 45(7). 605–608. 8 indexed citations
6.
Musch, E., Tilo Andus, Wolfgang Kruis, et al.. (2005). Interferon-β-1a for the Treatment of Steroid-Refractory Ulcerative Colitis: A Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Gastroenterology and Hepatology. 3(6). 581–586. 51 indexed citations
7.
8.
Musch, E., et al.. (2003). Intrapericardial Instillation of Mitoxantrone in Palliative Therapy of Malignant Pericardial Effusion. Oncology Research and Treatment. 26(2). 135–139. 9 indexed citations
9.
Musch, E., et al.. (2003). Amifostine plus erythropoietin in a patient with low-risk myelodysplastic syndrome. Annals of Hematology. 82(4). 244–246. 2 indexed citations
10.
Teuber, G, M. Pascu, Thomas Berg, et al.. (2003). Randomized, controlled trial with IFN-α combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. Journal of Hepatology. 39(4). 606–613. 34 indexed citations
11.
Musch, E., et al.. (2002). Induction and maintenance of clinical remission by interferon‐β in patients with steroid‐refractory active ulcerative colitis—an open long‐term pilot trial. Alimentary Pharmacology & Therapeutics. 16(7). 1233–1239. 38 indexed citations
12.
Musch, E., A. Gerritzen, Manfred Wiese, et al.. (1999). Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.. PubMed. 45(24). 2282–94. 9 indexed citations
13.
Musch, E., et al.. (1994). Lipid Peroxides in the Polychemotherapy of Cancer Patients. Chemotherapy. 40(1). 8–15. 78 indexed citations
14.
Musch, E., Jasna Peter‐Katalinić, Heinz Egge, et al.. (1992). Cellular kinetics of prednimustine versus chlorambucil plus prednisolone in vitro. Cancer Chemotherapy and Pharmacology. 29(4). 297–304. 1 indexed citations
15.
Loos, U., et al.. (1991). Comparative Pharmacokinetics of Chlorambucil and Prednimustine after Oral Administration. Oncology. 48(4). 334–342. 2 indexed citations
16.
17.
Musch, E., et al.. (1989). Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma. Cancer Chemotherapy and Pharmacology. 23(2). 76–80. 32 indexed citations
18.
Musch, E., et al.. (1989). Studies on the pharmacokinetics of chlorambucl and prednimustine in patients using a new high-performance liquid chromatographic assay. Cancer Chemotherapy and Pharmacology. 23(4). 208–212. 18 indexed citations
19.
Loos, U., et al.. (1988). The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma. European Journal of Clinical Pharmacology. 35(2). 187–193. 12 indexed citations
20.
Werner, A., et al.. (1988). Über die Verträglichkeit einer intraoperativen, intraperitonealen Chemotherapie bei fortgeschrittenen gynäkologischen Malignomen. Geburtshilfe und Frauenheilkunde. 48(8). 574–578. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Miriam Barbanti Breakdown of academic impact, for papers by Kazuko Nagase Breakdown of academic impact, for papers by Ward Jm Breakdown of academic impact, for papers by Tomonori Hada Breakdown of academic impact, for papers by Melinda J. Reese Breakdown of academic impact, for papers by Sarah L. Greig Breakdown of academic impact, for papers by Huw B. Jones Breakdown of academic impact, for papers by G. L. Floersheim Breakdown of academic impact, for papers by Fang Zhao Breakdown of academic impact, for papers by George Tang
Rankless by CCL
2026